AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
The European Commission has approved AbbVie's SKYRIZI for treating pediatric patients aged six and older with moderate to severe plaque psoriasis. The approval includes a new dosage option to support weight-based treatment for younger children.
Why it matters
This approval expands treatment options for a chronic condition that significantly impacts the quality of life and social development of pediatric patients.
NORTH CHICAGO, Ill. , June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Commission (EC) has approved SKYRIZI ® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg. 1
The article is a standard corporate press release regarding regulatory approval for a medical product.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in